{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:04:09Z","timestamp":1771427049665,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.medcli.2025.107118","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:07:03Z","timestamp":1752829623000},"page":"107118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["C\u00e1ncer de origen desconocido: diagn\u00f3stico, tratamiento y avances tecnol\u00f3gicos"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-8708","authenticated-orcid":false,"given":"Ferran","family":"Losa Gasp\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Legido D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"S\u00e1nchez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107118_bib0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canep.2019.06.006","article-title":"The currently declining incidence of cancer of unknown primary","volume":"61","author":"Rassy","year":"2019","journal-title":"Cancer Epidemiol."},{"issue":"Suppl 5","key":"10.1016\/j.medcli.2025.107118_bib0225","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0230","unstructured":"National Comprehensive Cancer Network. Version 2.2025, September 11, 2024. Disponible en: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/occult.pdf"},{"key":"10.1016\/j.medcli.2025.107118_bib0235","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12094-022-02806-x","article-title":"SEOM-GECOD clinical guideline for unknown primary cancer (2021)","volume":"24","author":"Losa","year":"2022","journal-title":"Clin Transl Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","article-title":"Molecular characterisation and liquid biomarkers in carcinoma of unknown primary (CUP): taking the \u2018U\u2019 out of \u2018CUP\u2019","volume":"120","author":"Conway","year":"2019","journal-title":"Br J Cancer."},{"key":"10.1016\/j.medcli.2025.107118_bib0250","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41416-019-0723-z","article-title":"Exploring the biological hallmarks of cancer of unknown primary: Where do we stand today?","volume":"122","author":"Rassy","year":"2020","journal-title":"Br J Cancer."},{"key":"10.1016\/j.medcli.2025.107118_bib0255","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41571-020-0359-1","article-title":"Progress in refining the clinical management of cancer of unknown primary in the molecular era","volume":"17","author":"Rassy","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0260","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): An open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.107118_bib0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: New routes to targeted therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0270","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0275","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","article-title":"Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary","volume":"77","author":"Kato","year":"2017","journal-title":"Cancer Res."},{"issue":"Suppl 5","key":"10.1016\/j.medcli.2025.107118_bib0280","doi-asserted-by":"crossref","first-page":"v597","DOI":"10.1093\/annonc\/mdx391.005","article-title":"Detection of therapeutic targets in carcinomas of unknown primary","volume":"28","author":"Clynick","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0285","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1634\/theoncologist.2011-0449","article-title":"A prospective comparison of 18F-FDG PET\/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site","volume":"17","author":"M\u00f8ller","year":"2012","journal-title":"Oncologist."},{"key":"10.1016\/j.medcli.2025.107118_bib0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.seminoncol.2008.10.009","article-title":"Pathologic evaluation of unknown primary cancer","volume":"36","author":"Oien","year":"2009","journal-title":"Semin Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0295","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.5858\/arpa.2014-0061-RA","article-title":"Immunohistochemistry in undifferentiated neoplasm\/tumor of uncertain origin","volume":"138","author":"Lin","year":"2014","journal-title":"Arch Pathol Lab Med."},{"key":"10.1016\/j.medcli.2025.107118_bib0300","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/PAP.0000000000000069","article-title":"Metastatic carcinoma of unknown primary: Diagnostic approach using immunohistochemistry","volume":"22","author":"Conner","year":"2015","journal-title":"Adv Anat Pathol."},{"key":"10.1016\/j.medcli.2025.107118_bib0305","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ctrv.2015.05.010","article-title":"Cancer of unknown primary origin in the genomic era: Elucidating the dark box of cancer","volume":"41","author":"Economopoulou","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.medcli.2025.107118_bib0310","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jmoldx.2011.04.004","article-title":"Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification","volume":"13","author":"Erlander","year":"2011","journal-title":"J Mol Diagn."},{"issue":"Suppl 5","key":"10.1016\/j.medcli.2025.107118_bib0315","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase iii trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0320","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: A multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0325","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.seminoncol.2008.10.006","article-title":"Treatment for patients with unknown primary cancer and favorable prognostic factors","volume":"36","author":"Hainsworth","year":"2009","journal-title":"Semin Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0330","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1200\/JCO.2003.12.104","volume":"21","author":"Culine","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0335","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1008369812295","article-title":"Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin","volume":"11","author":"Greco","year":"2000","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604818","article-title":"Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: A randomised prospective phase ii trial","volume":"100","author":"Huebner","year":"2009","journal-title":"Br J Cancer."},{"key":"10.1016\/j.medcli.2025.107118_bib0345","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/1097-0142(20010201)91:3<592::AID-CNCR1039>3.0.CO;2-5","article-title":"A randomized phase ii trial in patients with carcinoma of an unknown primary site","volume":"91","author":"Dowell","year":"2001","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2025.107118_bib0350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-007-0604-7","article-title":"Multicenter phase-ii trial of irinotecan plus oxaliplatin (IROX regimen) in patients with poor-prognosis cancer of unknown primary: a Hellenic cooperative oncology group study","volume":"62","author":"Briasoulis","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.medcli.2025.107118_bib0355","first-page":"162","article-title":"Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary","volume":"32","author":"Schuette","year":"2009","journal-title":"Onkologie."},{"key":"10.1016\/j.medcli.2025.107118_bib0360","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/cncr.25029","article-title":"Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon Oncology Research Consortium","volume":"116","author":"Hainsworth","year":"2010","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2025.107118_bib0365","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1002\/onco.13597","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary origin: Retrospective molecular classification considering the CUPISCO study design","volume":"26","author":"Ross","year":"2021","journal-title":"Oncologist."},{"key":"10.1016\/j.medcli.2025.107118_bib0370","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.4251","article-title":"Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary","volume":"231","author":"Tothill","year":"2013","journal-title":"J Pathol."},{"key":"10.1016\/j.medcli.2025.107118_bib0375","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.18632\/oncotarget.2574","article-title":"Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases","volume":"5","author":"Gatalica","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.medcli.2025.107118_bib0380","doi-asserted-by":"crossref","first-page":"44322","DOI":"10.18632\/oncotarget.10035","article-title":"Molecular driver alterations and their clinical relevance in cancer of unknown primary site","volume":"7","author":"L\u00f6ffler","year":"2016","journal-title":"Oncotarget."},{"issue":"Suppl 15","key":"10.1016\/j.medcli.2025.107118_bib0385","doi-asserted-by":"crossref","first-page":"e24162","DOI":"10.1200\/JCO.2018.36.15_suppl.e24162","article-title":"Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions","volume":"36","author":"Kr\u00e4mer","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0390","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0395","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol."},{"key":"10.1016\/j.medcli.2025.107118_bib0400","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.medcli.2025.107118_bib0405","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107118_bib0410","article-title":"La importancia de la psicooncolog\u00eda como parte integral del tratamiento en oncolog\u00eda","volume":"24","author":"Galindo V\u00e1zquez","year":"2023","journal-title":"Rev Digit Univ."},{"key":"10.1016\/j.medcli.2025.107118_bib0415","first-page":"6353","article-title":"Nationwide survey on family caregiver-perceived experiences of patients with cancer of unknown primary site","volume":"30","author":"Ishida","year":"2022","journal-title":"Support Care Cancer."},{"key":"10.1016\/j.medcli.2025.107118_bib0420","first-page":"1160","article-title":"Understanding and managing cancer of unknown primary","volume":"17","author":"Symons","year":"2008","journal-title":"Br J Nurs."},{"key":"10.1016\/j.medcli.2025.107118_bib0425","first-page":"8217","article-title":"Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): A cross-sectional multi-site study","volume":"30","author":"Guccione","year":"2022","journal-title":"Support Care Cancer."},{"key":"10.1016\/j.medcli.2025.107118_bib0430","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/bmjspcare-2013-000482","article-title":"Uncertainty and anxiety in the cancer of unknown primary patient journey: A multiperspective qualitative study","volume":"5","author":"Richardson","year":"2015","journal-title":"BMJ Support Palliat Care."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532500346X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532500346X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:06:00Z","timestamp":1771423560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002577532500346X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S002577532500346X"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107118","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C\u00e1ncer de origen desconocido: diagn\u00f3stico, tratamiento y avances tecnol\u00f3gicos","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"107118"}}